AstraZeneca today announced that it has purchased a biologics manufacturing facility in Longmont, Colorado from Amgen Inc. This facility will be used to support AstraZeneca’s existing operations at its nearby Boulder site also purchased from Amgen in September of 2015.
Darren Dasburg, Boulder Manufacturing Center Site Director, AstraZeneca, said: “The Longmont facility adds to our expanding biologics commercial manufacturing capabilities as we prepare for our exciting future biologic medicines. Integrating this site into our existing operations network will provide AstraZeneca and MedImmune, our global biologics research and development arm, with flexible biological manufacturing capacity to quickly bring new innovative treatments to patients.”
The site will be staffed over time and according to business needs as the company’s pipeline matures and expansions are deemed necessary.
NOTES TO EDITORS
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas – Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca-us.com
Abigal Bozarth +1 302 885 2677